PharmaEssentia Corp (6446):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:PharmaEssentia Corp (6446) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8013
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:台湾
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
PharmaEssentia Corp (PharmaEssentia) is a developer of therapeutic products for the treatment of human diseases. The company’s pipeline product includes P1101, a new generation PEG-Interferon-alpha-2b which is developed using PEGylation technology platform. Its pegylation technology platform is designed to increase the protein drug’s efficacy by prolonging its circulation in the bloodstreamd. PharmaEssentia’s products are used in the therapeutic areas of dermatology, hematology, infectious diseases and oncology. The company also develops oncology drug for various carcinomas, including pancreatic cancer, non-small cell lung cancer, bladder cancer and breast cancer. It collaborates with biotechnology companies, university research institutes, and pharmaceutical companies. PharmaEssentia is headquartered in Taipei, Taiwan.

PharmaEssentia Corp (6446) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PharmaEssentia Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
PharmaEssentia Amends Licensing Agreement with Athenex for Oraxol and Oratecan 10
Equity Offering 12
PharmaEssentia Raises USD88 Million in Public Offering of Shares 12
PharmaEssentia Raises USD20.5 Million in Rights Offering of Shares 13
PharmaEssentia Corp – Key Competitors 14
PharmaEssentia Corp – Key Employees 15
PharmaEssentia Corp – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PharmaEssentia Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PharmaEssentia Corp, Deals By Therapy Area, 2012 to YTD 2018 8
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
PharmaEssentia Amends Licensing Agreement with Athenex for Oraxol and Oratecan 10
PharmaEssentia Raises USD88 Million in Public Offering of Shares 12
PharmaEssentia Raises USD20.5 Million in Rights Offering of Shares 13
PharmaEssentia Corp, Key Competitors 14
PharmaEssentia Corp, Key Employees 15
PharmaEssentia Corp, Other Locations 16

List of Figures
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[PharmaEssentia Corp (6446):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • CMS Energy Corp (CMS):企業の財務・戦略的SWOT分析
    CMS Energy Corp (CMS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Empire Electric Association, Inc.:企業の戦略的SWOT分析
    Empire Electric Association, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Triumph Group Inc:企業の戦略・SWOT・財務情報
    Triumph Group Inc - Strategy, SWOT and Corporate Finance Report Summary Triumph Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Edge Therapeutics Inc (EDGE)-製薬・医療分野:企業M&A・提携分析
    Summary Edge Therapeutics Inc (Edge Therapeutics) is a clinical-stage biotechnology company that discovers, develops and commercializes a range of hospital-based therapies. The company offers hospital based therapies capable of transforming treatment paradigms in the management of life-threatening, …
  • Culp Inc (CULP):企業の財務・戦略的SWOT分析
    Culp Inc (CULP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Zogenix Inc (ZGNX):製薬・医療:M&Aディール及び事業提携情報
    Summary Zogenix Inc (Zogenix) is a pharmaceutical company with focus on central nervous system (CNS) disorders. It develops and commercializes therapies for rare CNS disorders. The company’s lead product candidate ZX008 (low dose fenfluramine) is intended for the treatment of Dravet syndrome and Len …
  • Chennai Petroleum Corp Ltd (CHENNPETRO):企業の財務・戦略的SWOT分析
    Chennai Petroleum Corp Ltd (CHENNPETRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Broadwind Energy, Inc. (BWEN):電力:M&Aディール及び事業提携情報
    Summary Broadwind Energy, Inc. (Broadwind) is a precision manufacturer of structures, equipment, and components for clean technology and other specialized applications. It offers a wide range of products from gears and gearing systems, to wind turbine towers, fabrications and industrial weldments. T …
  • Relmada Therapeutics Inc (RLMD):製薬・医療:M&Aディール及び事業提携情報
    Summary Relmada Therapeutics Inc (Relmada Therapeutics), formerly Camp Nine Inc, is a pharmaceutical company that develops and commercializes products for the treatment of central nervous system (CNS) diseases. The company’s product pipeline includes REL-1017 d-Methadone, an antagonist for the treat …
  • Steris Plc (STE):企業の財務・戦略的SWOT分析
    Steris Plc (STE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Wallenstam AB (WALL B):企業の財務・戦略的SWOT分析
    Summary Wallenstam AB (Wallenstam) is a construction company that offers building and property management solutions. The company's services include commercial and residential properties development, housing programs, property investment and management, urban development, property ownership services, …
  • Suntory Holdings Ltd:戦略・SWOT・企業財務分析
    Suntory Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Suntory Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Broncus Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Broncus Medical Inc (Broncus), formerly Broncus Technologies Inc is a medical device company that develops navigation, diagnostic and therapeutic technologies for the treatment of patients with lung disease. The company offers Archimedes system, a total lung access platform used for virtual …
  • Ferrovial, S.A.:企業の戦略・SWOT・財務分析
    Ferrovial, S.A. - Strategy, SWOT and Corporate Finance Report Summary Ferrovial, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Chegg, Inc.:企業のM&A・事業提携・投資動向
    Chegg, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Chegg, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Lifetech Scientific (Shenzhen) Co Ltd:企業の製品パイプライン分析2018
    Summary Lifetech Scientific (Shenzhen) Co Ltd (Lifetech Shenzhen), a subsidiary of Lifetech Scientific Corp, is a medical device company that offers minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases. The company provides products such as dilator, o …
  • University of Rochester-製薬・医療分野:企業M&A・提携分析
    Summary University of Rochester (UOR) is an educational university that offers research and development services. The university performs research in the areas of humanities, engineering medical education, medicine, geology, optics, economics, political theory, human behavior, and social and natural …
  • Grinners Catering (Australia) Pty Ltd:企業の戦略・SWOT・財務分析
    Grinners Catering (Australia) Pty Ltd - Strategy, SWOT and Corporate Finance Report Summary Grinners Catering (Australia) Pty Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Equinor ASA (EQNR):電力:M&Aディール及び事業提携情報
    Summary Equinor ASA (Equinor), formerly Statoil ASA, is an energy company. It focuses mainly on the exploration, development and production of crude oil and natural gas on the Norwegian Continental Shelf (NCS). The company also has operations in several of the important oil and gas provinces in the …
  • GQ Life Sciences Inc-製薬・医療分野:企業M&A・提携分析
    Summary GQ Life Sciences Inc (GQ Life Sciences), formerly GenomeQuest Inc, a subsidiary of Aptean Inc, is a life science information and search company that offers genomic software to search patents for biological sequences. The company provides lifequest, a patent search tool that provides a soluti …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆